Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and markets products that help improve the safety of patient care worldwide. The company offers specialty injectable pharmaceuticals, which include approximately 200 injectable generic drugs in multiple dosages and formulations; proprietary specialty injectables, including Precedex, a proprietary drug for sedation; Biosimilars that comprise Retacrit, a biosimilar erythropoietin, which is used primarily in the treatment of anemia in dialysis and in certain oncology applications; and ; and Nivestim, a biosimilar filgrastim used for the treatment of low white blood cells in patients who have received a chemotherapeutic agent. It also provides intravenous solutions and nutritional products; and contract manufacturing services. In addition, the company offers medication management products consisting of infusion pumps and dedicated administration sets; Hospira MedNet safety software system and related services; software applications and devices that support point-of-care medication administration; gravity administration sets; and other device products. Further, it is involved in the development/co-development of proprietary pharmaceutical products, such as Precedex, which is in Phase III clinical trial for procedural sedation; POSIDUR, a long-acting version of the anesthetic bupivacaine that is in Phase III clinical trial; Dyloject, a post-operative pain management drug; and ATIR, a personalized hematology product designed for blood cancer patients in need of allogeneic bone marrow transplantation who cannot locate a matched donor. The company serves hospitals, clinics, home healthcare providers, and long-term care facilities. It has various collaborative arrangements with Kiadis Pharma B.V.; DURECT Corporation; ChemGenex Pharmaceuticals Limited; and Bioceuticals Arzneimittel AG. The company was founded in 2003 and is headquartered in Lake Forest, Illinois.